Physician profile
Amanda Irons
NPI 1922132141
$3,450.37
in general payments reported to CMS, 2019-2025
20 companies · $727 in 2025
The $727 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $580 · 2023: $1,038 · 2024: $791 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.96 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $402.72 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $400.18 | 2021-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $383.17 | 2021-2024 | |
| Philips North America LLC | $304.58 | 2022-2025 | (Ck4) Mcot, Extended Holter, (Ck7) Extended Holter |
| Pfizer INC. | $282.68 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $229.34 | 2023 | Optimizer |
| Amgen INC. | $222.16 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $147.59 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.26 | 2021-2025 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $71.20 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $66.89 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $65.82 | 2021-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $61.44 | 2022 | |
| Bridgebio Pharma, INC. | $60.69 | 2025 | Attruby |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.62 | 2023-2025 | Xact |
| Alnylam Pharmaceuticals INC. | $40.42 | 2024-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $34.71 | 2023 | Farxiga |
| Esperion Therapeutics, INC. | $23.74 | 2021 | |
| Heartflow, INC. | $15.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Irons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.